Braidwell LP Grows Stake in Vera Therapeutics, Inc. $VERA

Braidwell LP grew its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 7.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 564,724 shares of the company’s stock after acquiring an additional 40,900 shares during the quarter. Braidwell LP’s holdings in Vera Therapeutics were worth $24,232,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Optimize Financial Inc grew its position in Vera Therapeutics by 1.5% during the 4th quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after purchasing an additional 256 shares during the last quarter. Virtus Investment Advisers LLC boosted its stake in Vera Therapeutics by 5.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after purchasing an additional 290 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Vera Therapeutics by 2.4% during the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after purchasing an additional 424 shares in the last quarter. Invesco Ltd. raised its position in Vera Therapeutics by 2.0% in the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after buying an additional 550 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its stake in Vera Therapeutics by 5.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 15,027 shares of the company’s stock valued at $761,000 after acquiring an additional 778 shares during the period. Institutional investors own 99.21% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on VERA shares. TD Cowen lifted their price target on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. HC Wainwright lowered their price target on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, August 12th. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Raymond James Financial reissued a “strong-buy” rating and issued a $84.00 target price on shares of Vera Therapeutics in a report on Tuesday, August 11th. Finally, Wedbush reaffirmed a “neutral” rating and set a $34.00 price target on shares of Vera Therapeutics in a research report on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $81.15.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock opened at $35.66 on Thursday. The stock has a market cap of $2.57 billion, a P/E ratio of -6.09 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The stock’s fifty day moving average is $36.10 and its 200 day moving average is $37.52. Vera Therapeutics, Inc. has a one year low of $21.71 and a one year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period in the previous year, the firm posted ($1.20) earnings per share. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -6.43 earnings per share for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.